Home
Team
Science & Research
News
Feb 12, 2025
Research on combined CBD and THC for migraine, by E. Zorrilla et al., was named Cephalalgia Editor's Choice for February 2025 by the International Headache Society.
Sep 19, 2024
Delphian Therapeutics received a $2.9M Phase 2 SBIR grant from the U.S. National Institutes of Health to advance its patented CBD:THC migraine formulation through IND…
May 15, 2024
Delphian Therapeutics closed a $2.7M seed round to advance S1-221, its patented CBD:THC combination for migraine, into Phase 1 clinical trials. The program is funded in part by NIH and the Migraine Research Foundation.
